IXICO plc announced that it has signed a contract with a new client. IXICO will provide its imaging services in a clinical trial of a novel therapeutic to treat Progressive Supranuclear Palsy, a rare neurodegenerative disease. The contract value is circa USD 1.7 million (circa PS1.3 million), over a 4-year term.

The World Health Organization defines a rare disease as one that strikes fewer than 65 per 100,000 people.